logo
BlueCrest Health Group Rebrands QuickSilver Counseling Center as BlueCrest Counseling Center

BlueCrest Health Group Rebrands QuickSilver Counseling Center as BlueCrest Counseling Center

06/25/2025, New Providence, NJ // KISS PR Brand Story PressWire //
BlueCrest Health Group, the parent company of the acclaimed BlueCrest Recovery Center and BlueCrest Detox in New Jersey, is proud to announce that QuickSilver Counseling Center has officially rebranded as BlueCrest Counseling Center.
This rebranding reflects BlueCrest Health Group's commitment to delivering consistent, high-quality outpatient services under a unified name that aligns with the group's mission to provide compassionate, evidence-based care. BlueCrest Counseling Center continues to offer the same comprehensive outpatient programs, including intensive outpatient programs (IOP), gender-specific rehab programs, and specialized addiction therapy services, now under the BlueCrest brand that clients trust.
'Our counseling center reflects our commitment to empowering individuals on their path to recovery. We're honored to provide accessible, compassionate care that helps clients build lasting wellness and reclaim their lives.'
- Richard Hession, Chief Executive Officer, BlueCrest Health Group
Located at 571 Central Ave, Suite 108, New Providence, NJ 07974, BlueCrest Counseling Center remains a safe and supportive environment where clients can work toward long-term recovery while developing the skills and resilience needed to thrive. The center's multidisciplinary team offers personalized therapy options such as cognitive-behavioral therapy (CBT), dialectical behavior therapy (DBT), trauma therapy, and family therapy, tailored to each client's unique needs and goals.
For more information about BlueCrest Counseling Center's services or to inquire about admissions, please call (888) 477-8941 or email [email protected].
About BlueCrest Health Group
BlueCrest Health Group provides individualized, evidence-based care for substance use and co-occurring mental health disorders. Known for its deeply compassionate, client-centered approach, the group operates BlueCrest Recovery Center, BlueCrest Counseling Center, and BlueCrest Detox in New Jersey.
###
Media Contact
Devon Zanaras
(973) 298-5776
newsroom: news.38digitalmarket.com
Source published by Submit Press Release >> BlueCrest Health Group Rebrands QuickSilver Counseling Center as BlueCrest Counseling Center
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Smartwatches Won't Fix the Burnout Crisis in Medicine
Smartwatches Won't Fix the Burnout Crisis in Medicine

Medscape

time27 minutes ago

  • Medscape

Smartwatches Won't Fix the Burnout Crisis in Medicine

This transcript has been edited for clarity. Welcome to Impact Factor , your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson from the Yale School of Medicine. Burnout is a huge problem across multiple professions in the United States. Grades K-12 teachers have about a 50% burnout rate. So do people in quality assurance. But I was unable to find a profession with a higher rate of burnout, or a higher potential for harm from burnout, than — you guessed it — physicians. A 2022 survey found that 63% of physicians had burnout, rates that have been among the highest of all US workers since 2011. And this is a huge problem. When docs are burned out, they are more likely to commit medical errors, be named in malpractice suits, and even exhibit racial biases. Administrators of health systems have taken notice. But their solutions have often been criticized as tone-deaf. 'Mandatory burnout workshops' are not helping anyone's burnout, I promise you. So I was a bit concerned by a study that came out this week that offered a relatively simple solution to what is a really complex problem. Can you actually cut burnout in half by giving physicians a smartwatch? Before we dig into the study, let's talk about burnout a little bit. I think there's sort of a Potter Stewart definition of burnout: 'I know it when I see it.' But the real description comes from Christina Maslach, who characterized it as a psychological syndrome brought about by chronic occupational stress characterized by emotional exhaustion, depersonalization or cynicism, and a reduced sense of personal accomplishment. Sound familiar? I know. It's not uncommon. And it goes without saying that depersonalization and cynicism are just terrible traits to have in a doctor. It's not just workload that leads to burnout, according to most psychologists; it's this combination of workload and a feeling that you don't have autonomy. That you are not the master of your fate or the captain of your soul. Big issues. So how is a smartwatch supposed to help? Well, the idea isn't crazy. Smartwatches are miniature biofeedback devices. They tell you about your heart rate, your step count, how much you slept. Those little data points can lead to some real behavior change. This is anecdotal, but multiple people have told me they've cut back on drinking alcohol because they noticed that their smartwatch-reported sleep quality is worse on nights that they drink. Researchers at the Mayo Clinic and University of Colorado thought that maybe giving smartwatches to physicians would lead them to make small lifestyle changes, like getting more sleep, that would reduce this problem of burnout. Here's how the trial worked, as reported in JAMA Network Open . One hundred and eighty-four physicians — about half attendings, half residents and fellows, and about 60% female — were randomized to two groups. One group got a smartwatch, specifically the Venu 2 Plus from Garmin, to wear for 6 months. The other group got nothing. Well, to be fair, they got a smartwatch as well — just after a 6-month wait so the team would have 6 months of high-quality comparison data. At the beginning of the study and several times over those 6 months, the participants took surveys about their mental health: a resilience survey, a quality-of-life survey, a depression survey, a stress survey, a sleep survey and, importantly, a burnout survey. At baseline, 50% of people in the intervention arm were burned out and 43% were burned out in the control arm. After 6 months, burnout dropped to 41% in the intervention arm and rose to 51% in the control arm. The difference here was not technically statistically significant, but after accounting for the fact that burnout was higher at baseline in the intervention group, the team concluded that the odds of burnout were about 50% lower after 6 months of the smartwatch intervention. I know statistics can get confusing in situations like this. I think sometimes it helps just to look at the graph and make your own judgment: Burnout down a bit with a smartwatch, up a bit without a smartwatch. Fine. There was also about a 20% improvement in resilience scores, while there were no differences in quality of life, depression, or stress scores. So… is that it? Have we solved this problem plaguing all of healthcare and multiple other industries across the United States? Smartwatches? My fear is that some C-suite execs will look at this study and think they can cut burnout rates in half by sending a bunch of smartwatches around. Maybe it seems obvious to you that it wouldn't actually work, but let's break down a bit how the results of this study may be somewhat skewed. The most important thing to note is that this study was not blinded. The people in the smartwatch group knew they were in the smartwatch group because… they were wearing the smartwatch. It's hard to imagine a way to blind this study, to be fair, although I suppose you could give everyone a smartwatch but half the people get fake data or something. But once you know that you are in the intervention group, biases in your answers creep in. Just imagine you're in the study. At baseline, you take these surveys, then they give you a smartwatch, and 6 months later you take a bunch of surveys again. Maybe you skew your answers a bit, even unconsciously, because you like the people running the study or science in general, or maybe even smartwatches. The authors acknowledge this but minimize it, suggesting that if this 'social desirability bias' was present, it should improve scores across all the surveys. I mean, okay, but to be honest, the score differences are pretty marginal across the board, so I don't find that argument very compelling. The real issue here is that this study puts the locus of control in the wrong place, as many burnout interventions do. It puts the responsibility for burnout on the shoulders of the burned-out physicians. It suggests we can tolerate our jobs better if we just change our outlook: Sleep more, meditate more, live in the moment, do tai chi, etc. But I would argue that the problem with burnout is not in the mind of the physician; the problem is the system in which we work. More than 75% of physicians in the United States today are employed by hospitals, health systems, or other corporate entities. The private-practice model is rapidly dying and the physician workforce is learning what it means to be labor instead of management. They are feeling what it is like to be exploited, for lack of a better word — pushed to see more patients in less time, pushed to generate more RVUs, pushed to work weekends and nights to increase margins. It's not what they signed up for. The problem of burnout is from the system. If you want to cut rates in half, you don't send docs a smartwatch. You give them more time to see fewer patients. You change the insurance system that leaves us on the phone arguing for prior authorization for hours at a time. And if that affects the bottom line of the health system, you look for cuts in the — and this is true — 10 administrators for each physician in the US. Look, I love my smartwatch. It helps me delete emails while I'm waiting for the elevator. But the solution to physician burnout is not here. It's out there.

TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

Yahoo

timean hour ago

  • Yahoo

TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

Transforms present balance sheet with significant reduction in liabilities Largest shareholder is long-term strategic investor NEW YORK, August 19, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. "The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities," said TNF President and Chief Medical Officer, Mitchell Glass, M.D. "We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage." The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts Investor Contact: Sign in to access your portfolio

Michigan lawmakers call on HHS to explain withholding funds for disability advocate groups
Michigan lawmakers call on HHS to explain withholding funds for disability advocate groups

CBS News

timean hour ago

  • CBS News

Michigan lawmakers call on HHS to explain withholding funds for disability advocate groups

A group of Michigan lawmakers is calling on the Department of Health and Human Services to explain why it took back more than $130,000 in funds that were earmarked for legal support for those with disabilities. Whether it's dealing with insurance or getting legal support for abuse, neglect, or human rights cases, these lawmakers say those with disabilities could be on their own if these funds don't come through. "Attacks like this take us back and repeal so much of the progress that we've made," said Democratic U.S. Rep. Hillary Scholten. Scholten is one of those representatives who say they're looking to hold HHS accountable for withholding these funds. The organization receiving them, Disability Rights Michigan, says in part, "The pullback of these funds threatens our ability to investigate abuse and neglect, ensure safe and appropriate discharges, and advocate for children and adults who depend on Disability Rights Michigan for legal protections." Scholten says withholding funds defeats the purpose of having a resource like this. "A program like that can only continue to exist if we have a full pot of resources available to help individuals with these severe disabilities," she said. Fellow Democratic U.S. Rep. Shri Thanedar also signed the letter, which raised several questions about why the funds were rescinded, when and if they can expect them to be awarded, and why the distribution changed from a lump sum amount to being released as installments. "I signed onto that letter so we can get some answers on the programs being gutted and demand those funds be released for the sake of every American," Thanedar said. These lawmakers are giving HHS 30 days to respond to their questions before they take further action. CBS News Detroit reached out to HHS for comment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store